Here's which of the InnovationMap Awards finalists are hiring

growing biz

Want to work for one of the top startups in Houston? These ones are hiring. Photo by Tima Miroshnichenko from Pexels

After scouring Houston for the best of the Houston innovation ecosystem and evaluating dozens of companies, InnovationMap has announced the finalists in its inaugural awards. But which of these companies are growing their teams?

Turns out, almost all of them have open positions — some planning to double their teams over the next year. In fact, the 28 companies that make up our cohort of finalists are looking for over 250 new employees — some have these positions open now and others are seeking these new team members over the next 12 months.

Let's look at how many new hires these top startups are looking for.

Biggest gains

The InnovationMap Awards finalist with the loftiest hiring goal is Liongard, which is a finalist in the People's Choice: Startup of the Year category. Liongard — a platform that helps IT companies automatically discover, document, and audit their customers' IT systems — is looking to fill 70 positions over the next year. The company, founded in 2015, has just over 100 employees now.

The startup finalist with the second highest hiring goals is Nanotech, a material science company with a mission to fireproof the world and reduce energy consumption. Nanotech is looking to hire over 40 new employees in the next 12 months, which would almost triple its current staff of 15. Founded in 2019 by Mike Francis, the company is a finalist in both the Energy Transition and People's Choice categories.

Another People's Choice finalist, GoCo, and its all-in-one employee management platform, is currently looking to grow its team by adding 20 new employees to its staff of 53. The company was founded in 2015 and has since raised over $12 million in VC funding.

Also looking to grow their team by 20 new hires is Hello Alice — a small business owner's passport through entrepreneurship that helps with networking, raising capital, and accessing growth tools. The company, co-founded by Carolyn Rodz, is up for an award in the BIPOC-Founded, Female-Founded, and People's Choice categories.

GoExpedi, whose founder and CEO Timothy Neal is a finalist in the Top Founder Under 40 category, currently has 17 positions open at the moment and is looking to add those new hires into its team of over 150 employees. The e-commerce, supply chain, and analytics company is streamlining procurement for industrial and energy MRO (maintenance, repair and operations).

While Female-Founded Business finalist RingOn — a wearable GPS tracker that is also a panic button that's designed for school kids and with an impact-driven mission of ending child trafficking — is only currently looking for six new hires, the company is expecting to hiring another 15 new employees next year. Right now, the company's employee count is at three.

Steady growth

A few of the awards finalists are sporting hiring goals in the seven to 12 new staffers range. Space Tech finalist NANCO Aero, which is developing package- and person-carrying air vehicles, is hiring a dozen new employees — a big goal considering the company currently has just four employees.

Enercross LLC, automation software for the energy industry, is a finalist in the Energy Transition category and is looking to add 11 new people to its team of 42. Meanwhile Sports Tech finalist sEATz — a mobile ordering and delivery platform for food, drinks, and merchandise at large events — is looking to about double its team of 10 over the few months.

Health Tech finalist Medical Informatics Corp. is the creator of Sickbay, which features web-based applications that transform data into actionable information to help care teams make better, faster decisions. The company has seven open positions to grow its team of 36.

Seeking selectively

The following InnovationMap Awards finalists are looking to grow their teams with between two and six new hires:

  • Allotrope Medical — creator of StimSite, a device that improves surgical safety and efficiency in millions of operations performed every year.
  • CaseCTRL — using artificial intelligence and automation to streamline surgical scheduling.
  • Cemvita Factory — engineering microbes that eat CO2 and produce valuable chemicals.
  • Cheers Health — creating products that are designed to support your liver and help you feel better after consuming alcohol.
  • Cognitive Space — providing a scalable satellite constellation management solution to the space industry.
  • Data Gumbo — creator of an interconnected industrial smart contract network secured and powered by blockchain.
  • DonateStock — simplifying the process of donating stock and helping nonprofits solicit, process, and manage stock donations.
  • FitLift — a wearable device and mobile platform that tracks motion and gives real-time feedback on lifting technique, allowing trainers, and athletes to drive results.
  • LAMIK Beauty — a tech-enabled clean color cosmetics company focusing on women of all diverse backgrounds
  • Molecule Software — creator of a leading cloud-native energy trading software.
  • re:3D Inc. — producer of large, affordable industrial 3D printers, and services that can print with new or recycled filament, pellets, or flake.
  • Saranas — creator of the Early Bird, the first and only FDA-approved bleed detection system for endovascular procedures.
  • Starling Medical — using AI and telehealth enabled medical devices to enable millions with bladder dysfunctions to be able to urinate safely and conveniently again.
  • Topl — impact monetization engine that enables digital and sustainable transformation across value chains and empowers the monetization of impact verified on the Topl Blockchain.
  • Zibrio Inc. — a fall prevention solution that empowers both clinicians and patients for better outcomes.

Find out which of these employers take home the win at the September 8 event at The Cannon - West Houston. Honorees, sponsors, judges, and their guests will celebrate in person, and the rest of the innovation community is invited to tune in to the livestream. Click here to RSVP.

Sponsorships are still available! If you are interested in partnering with InnovationMap as a sponsor of this event, send an email to awards@innovationmap.com.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings